Alun Parsons

Helsinki, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.

TP53 mutation drives unique transcriptional and functional vulnerabilities independent of del(17p) in multiple myeloma.

Journal: iScience

Published: February 23, 2026

Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations.

Targeting acute myeloid leukemia resistance with two novel combinations demonstrate superior efficacy in TP53, HLA-B, MUC4 and FLT3 mutations.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 08, 2025

Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia.

Predictors of response and rational combinations for the novel MCL-1 inhibitor MIK665 in acute myeloid leukemia.

Journal: Molecular oncology

Published: February 06, 2025

DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.

DEK::NUP214 acts as an XPO1-dependent transcriptional activator of essential leukemia genes.

Journal: Leukemia

Published: October 15, 2024

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

Journal: Blood

Published: April 11, 2024

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.

Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia.

Journal: Haematologica

Published: June 30, 2022

CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia.

CKS1 inhibition depletes leukemic stem cells and protects healthy hematopoietic stem cells in acute myeloid leukemia.

Journal: Science translational medicine

Published: June 22, 2022

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.

Journal: Signal transduction and targeted therapy

Published: May 20, 2022

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.

FLT3-ITD allelic ratio and HLF expression predict FLT3 inhibitor efficacy in adult AML.

Journal: Scientific reports

Published: July 14, 2021

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma.

S100 Calcium Binding Protein Family Members Associate With Poor Patient Outcome and Response to Proteasome Inhibition in Multiple Myeloma.

Journal: Frontiers in cell and developmental biology

Published: June 09, 2021

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia.

Journal: Cancer discovery

Published: June 08, 2021

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.

Heterogeneous modulation of Bcl-2 family members and drug efflux mediate MCL-1 inhibitor resistance in multiple myeloma.

Journal: Blood advances

Published: November 16, 2020

Showing 1-12 of 27

Last Updated: 09/26/2026